Literature DB >> 20303190

Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women.

Atif N Qasim1, Seth S Martin, Nehal N Mehta, Megan L Wolfe, James Park, Stanley Schwartz, Mark Schutta, Nayyar Iqbal, Muredach P Reilly.   

Abstract

BACKGROUND: Lp(a), implicated in both atherogenesis and thrombosis pathways, varies significantly by demographic and metabolic factors, providing challenges for its use in Coronary Heart Disease (CHD) risk. The purpose of this study was to investigate whether type-2 diabetic subjects, relative to non-diabetics, might benefit more from Lp(a) measurement in the prediction of CHD risk, as measured by coronary artery calcium (CAC).
METHODS: We performed cross sectional analyses in two community-based studies: the Penn Diabetes Heart Study [N = 1299 with type-2 diabetes] and the Study of Inherited Risk of Coronary Atherosclerosis [N = 860 without diabetes].
RESULTS: Blacks had 2-3 fold higher Lp(a) levels than whites in diabetic and non-diabetic samples. There was significant difference by gender (interaction p<0.001), but not race, in the association of Lp(a) with CAC in type-2 diabetic subjects. In age and race adjusted analysis of diabetic women, Lp(a) was associated with CAC [Tobit regression ratio 2.76 (95% CI 1.73-4.40), p<0.001]. Adjustment for exercise, medications, Framingham risk score, metabolic syndrome, BMI, CRP and hemoglobin A1c attenuated this effect, but the association of Lp(a) with CAC remained significant [2.25, (1.34-3.79), p = 0.002]. This relationship was further maintained in women stratified by race, or by the use of HRT or lipid lowering drugs. In contrast, Lp(a) was not associated with CAC in diabetic men, nor in non-diabetic men and women.
CONCLUSIONS: Lp(a) is a strong independent predictor of CAC in type-2 diabetic women, regardless of race, but not in men. Lp(a) does not relate to CAC in men or women without type-2 diabetes.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303190      PMCID: PMC3132301          DOI: 10.1016/j.ijcard.2010.02.021

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  36 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

Review 2.  Lipoprotein(a): a unique risk factor for cardiovascular disease.

Authors:  Erdembileg Anuurad; Michael B Boffa; Marlys L Koschinsky; Lars Berglund
Journal:  Clin Lab Med       Date:  2006-12       Impact factor: 1.935

3.  Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study.

Authors:  Rudy Guerra; Zhaoxia Yu; Santica Marcovina; Ronald Peshock; Jonathan C Cohen; Helen H Hobbs
Journal:  Circulation       Date:  2005-03-21       Impact factor: 29.690

4.  A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes.

Authors:  I Shai; M B Schulze; J E Manson; M J Stampfer; N Rifai; F B Hu
Journal:  Diabetologia       Date:  2005-06-22       Impact factor: 10.122

Review 5.  A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment?

Authors:  Santica M Marcovina; Marlys L Koschinsky
Journal:  Semin Vasc Med       Date:  2002-08

6.  The importance of serum lipoprotein (a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States.

Authors:  G H Dahlén; S R Srinivasan; H Stenlund; W A Wattigney; S Wall; G S Berenson
Journal:  J Intern Med       Date:  1998-11       Impact factor: 8.989

7.  Impairment of endothelial function induced by glyc-oxidized lipoprotein a [Lp(a)].

Authors:  J Galle; B Winner; E Conzelmann; C Wanner
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  1998-11       Impact factor: 1.770

8.  Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.

Authors:  Jacqueline Suk Danik; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2008-07-08       Impact factor: 24.094

9.  Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data.

Authors:  Anna Bennet; Emanuele Di Angelantonio; Sebhat Erqou; Gudny Eiriksdottir; Gunnar Sigurdsson; Mark Woodward; Ann Rumley; Gordon D O Lowe; John Danesh; Vilmundur Gudnason
Journal:  Arch Intern Med       Date:  2008-03-24

10.  Adipokines, insulin resistance, and coronary artery calcification.

Authors:  Atif Qasim; Nehal N Mehta; Mahlet G Tadesse; Megan L Wolfe; Thomas Rhodes; Cynthia Girman; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2008-07-15       Impact factor: 24.094

View more
  19 in total

1.  The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes.

Authors:  Nikolaos P E Kadoglou; Grigorios Fotiadis; Zoi Athanasiadou; Ioulia Vitta; Stylianos Lampropoulos; Ioannis S Vrabas
Journal:  Endocrine       Date:  2012-03-11       Impact factor: 3.633

2.  Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications.

Authors:  Radhakrishnan Chandni; Kollengode Parameswaran Ramamoorthy
Journal:  World J Diabetes       Date:  2012-05-15

Review 3.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

4.  Evaluating the Potential Association Between Lipoprotein(a) and Atherosclerosis (from the Mediators of Atherosclerosis Among South Asians Living in America Cohort).

Authors:  Mark D Huffman; Namratha R Kandula; Abigail S Baldridge; Michael Y Tsai; Dorairaj Prabhakaran; Alka M Kanaya
Journal:  Am J Cardiol       Date:  2018-12-19       Impact factor: 2.778

Review 5.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

6.  Association of lipoprotein subfractions and coronary artery calcium in patient at intermediate cardiovascular risk.

Authors:  Borut Jug; Jenny Papazian; Robert Lee; Matthew J Budoff
Journal:  Am J Cardiol       Date:  2012-11-07       Impact factor: 2.778

7.  Cardiovascular risk factors and mitral annular calcification in type 2 diabetes.

Authors:  Atif N Qasim; Hashmi Rafeek; Suraj P Rasania; Timothy W Churchill; Wei Yang; Victor A Ferrari; Saurabh Jha; Stephen M Master; Claire K Mulvey; Karen Terembula; Chris Dailing; Matthew J Budoff; Steven M Kawut; Muredach P Reilly
Journal:  Atherosclerosis       Date:  2012-12-05       Impact factor: 5.162

8.  Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis.

Authors:  Brian T Steffen; George Thanassoulis; Daniel Duprez; James H Stein; Amy B Karger; Mathew C Tattersall; Joel D Kaufman; Weihua Guan; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

9.  C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome.

Authors:  Nilgün Güdücü; Herman Işçi; Alin Başgül Yiğiter; Ilkkan Dünder
Journal:  J Turk Ger Gynecol Assoc       Date:  2012-12-01

10.  Coronary calcification is associated with elevated serum lipoprotein (a) levels in asymptomatic men over the age of 45 years: A cross-sectional study of the Korean national health checkup data.

Authors:  Young Hak Chung; Byoung-Kwon Lee; Hyuck Moon Kwon; Pil-Ki Min; Eui-Young Choi; Young Won Yoon; Bum-Kee Hong; Se-Joong Rim; Jong-Youn Kim
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.